Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.
Marc FerrantePeter M IrvingMaria T AbreuJeffrey AxlerXiang GaoQian CaoToshimitsu FujiiAstrid RauschJoanna TorresEzequiel NeimarkAlexandra SongKori WallaceKristina KligysSofie BergXiaomei LiaoQing ZhouJasmina KalabicBrian FeaganRemo PanaccionePublished in: Journal of Crohn's & colitis (2023)
Subcutaneous risankizumab maintenance therapy results in durable improvement in clinical and endoscopic outcomes over 1 year in patients with moderately to severely active Crohn's disease.